Swift S, Duffy S, Lang S. 2020. Impact of tumor heterogeneity and tissue sampling for genetic mutation testing: a systematic review and post hoc analysis. J Clin Epidemiology 2020; 126, 45-55. https://doi.org/10.1016/j.jclinepi.2020.06.010.


Lang S, Swift S, Duffy S, et al . 2019. Taking account of tumour heterogeneity in systematic reviews. BMJ Evidence-Based Medicine 2019;24:A44. http://dx.doi.org/10.1136/bmjebm-2019-EBMLive.authorindex

Lang SH, Swift SL, White H, Misso K, Kleijnen J, & Quek RG. (2019). A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer. International Journal of Oncology, 55, 597-616. https://doi.org/10.3892/ijo.2019.4842


Collins AT, Lang SH. 2018. A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine. PeerJ 6:e5981 https://doi.org/10.7717/peerj.5981

Westwood M, Ramaekers B, Lang S, Grimm S, Deshpande S, de Kock S, et al. Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 2018 Aug;22(44):1–264. Available from: https://www.journalslibrary.nihr.ac.uk/hta/hta22440

Grimm SE, Armstrong N, Ramaekers BLT, Pouwels X, Lang S, et al. Nivolumab for treating metastatic or unresectable urothelial cancer: an Evidence Review Group perspective of a NICE single technology appraisal. Pharmacoeconomics 2018 Oct 6. doi: 10.1007/s40273-018-0723-5.

Ramaekers BLT, Wolff R, van Giessen A, Pouwels X, Fayter D, Lang S, et al. Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 2018 Mar;36(3):285–8. Available from: http://link.springer.com/10.1007/s40273-017-0591-4

Pouwels XGLV, Wolff R, Ramaekers BLT, Van Giessen A, Lang S, Ryder S, et al. Ticagrelor for Secondary Prevention of Atherothrombotic Events After Myocardial Infarction: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. 2018 May;36(5):533–43. Available from: http://link.springer.com/10.1007/s40273-017-0607-0

Lang S, Armstrong N, Deshpande S, Ramaekers B, Grimm S, de Kock S, et al. Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine. 2018 Jun 25;000456321878272. Available from: http://journals.sagepub.com/doi/10.1177/0004563218782722

Navone NM, et al., 2018. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models. The Prostate, 78(16), pp.1262–1282. Available at: https://onlinelibrary.wiley.com/doi/abs/10.1002/pros.23701.

Pellacani D, et al., 2018. Phenotype-independent DNA methylation changes in prostate cancer. British journal of cancer, p.33. Available at: http://eprints.whiterose.ac.uk/133612/ [Accessed August 9, 2018].


Westwood M, Lang S, Armstrong N, van Turenhout S, Cubiella J, Stirk L, et al. Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. BMC Medicine. 2017 Dec;15(1). Available from: http://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-017-0944-z

Westwood M, Corro Ramos I, Lang S, Luyendijk M, Zaim R, Stirk L, et al. Faecal immunochemical tests to triage patients with lower abdominal symptoms for suspected colorectal cancer referrals in primary care: a systematic review and cost-effectiveness analysis. Health Technology Assessment. 2017 May;21(33):1–234. Available from: https://www.journalslibrary.nihr.ac.uk/hta/hta21330

Collins A, Ross J, Lang SH. A systematic review of the asymmetric inheritance of cellular organelles in eukaryotes: A critique of basic science validity and imprecision. Prigent C, editor. PLOS ONE. 2017 May 31;12(5):e0178645. Available from: http://dx.plos.org/10.1371/journal.pone.0178645

Butler DE, et al., 2017. Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. Oncotarget, 8(34), pp.56698–56713. Available at: http://dx.doi.org/10.18632/oncotarget.18082.

Nappo G, et al., 2017. The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. Oncogenesis, 6(5), p.e342. Available at: http://dx.doi.org/10.1038/oncsis.2017.23.

Taurozzi AJ, et al., 2017. Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program. PloS one, 12(11), p.e0188228. Available at: http://dx.doi.org/10.1371/journal.pone.0188228.


Westwood M, Ramaekers B, Lang S, Armstrong N, Noake C, de Kock S, et al. ImmunoCAP® ISAC and Microtest for multiplex allergen testing in people with difficult to manage allergic disease: a systematic review and cost analysis. Health Technology Assessment. 2016 Sep ;20(67):1–178. Available from: https://www.journalslibrary.nihr.ac.uk/hta/hta20670/

Frame FM, et al., 2016. Harvesting Human Prostate Tissue Material and Culturing Primary Prostate Epithelial Cells. Methods in molecular biology , 1443, pp.181–201. Available at: http://dx.doi.org/10.1007/978-1-4939-3724-0_12.

Rane JK, Erb, H.H.H., et al., 2016. Inhibition of the glucocorticoid receptor results in an enhanced miR-99a/100-mediated radiation response in stem-like cells from human prostate cancers. Oncotarget, 7(32), pp.51965–51980. Available at: http://dx.doi.org/10.18632/oncotarget.10207.

Rane JK, Greener S, et al., 2016. Telomerase Activity and Telomere Length in Human Benign Prostatic Hyperplasia Stem-like Cells and Their Progeny Implies the Existence of Distinct Basal and Luminal Cell Lineages. European urology, 69(4), pp.551–554. Available at: http://dx.doi.org/10.1016/j.eururo.2015.09.039.


Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Lang S et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015 Jun 23;313(24):2456. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.6358

Korobelnik J-F, Kleijnen J, Lang SH, Birnie R, Leadley RM, Misso K, et al. Systematic review and mixed treatment comparison of intravitreal aflibercept with other therapies for diabetic macular edema (DME). BMC Ophthalmology. 2015 Dec;15(1). Available from: http://bmcophthalmol.biomedcentral.com/articles/10.1186/s12886-015-0035-x

Rane JK, Ylipää A, et al., 2015. Construction of therapeutically relevant human prostate epithelial fate map by utilising miRNA and mRNA microarray expression data. British journal of cancer, 113(4), pp.611–615. Available at: http://dx.doi.org/10.1038/bjc.2015.262.

Rane JK, Scaravilli M, et al., 2015. MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. European urology, 67(1), pp.7–10. Available at: http://dx.doi.org/10.1016/j.eururo.2014.09.005.

Wanger TM, et al., 2015. Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17. Cellular signalling, 27(7), pp.1325–1335. Available at: http://dx.doi.org/10.1016/j.cellsig.2015.03.017.

Zoni E et al., 2015. miR-25 Modulates Invasiveness and Dissemination of Human Prostate Cancer Cells via Regulation of αv- and α6-Integrin Expression. Cancer research, 75(11), pp.2326–2336. Available at: http://dx.doi.org/10.1158/0008-5472.CAN-14-2155.


Leadley RM, Lang S, Misso K, Bekkering T, Ross J, Akiyama T, et al. A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases. Orphanet Journal of Rare Diseases. 2014 Dec;9(1). Available from: http://ojrd.biomedcentral.com/articles/10.1186/s13023-014-0173-x

Lang S, Armstrong N, Noake C, Kleijnen J. A systematic review to evaluate the effectiveness of enzyme replacement therapy for lysosomal storage disorders in comparison to the treatment of similar diseases with higher prevalence. RARE DISEASES AND ORPHAN DRUGS An International Journal of Public Health. 2014;1(2):43–61.

Pellacani D, et al., 2014. DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. Cell death and differentiation, 21(5), pp.761–773. Available at: http://www.nature.com/cdd/journal/v21/n5/abs/cdd2013202a.html.

Rane JK, et al., 2014. Conserved two-step regulatory mechanism of human epithelial differentiation. Stem cell reports, 2(2), pp.180–188. Available at: http://dx.doi.org/10.1016/j.stemcr.2014.01.001.

Important papers pre-2014

Kroon P. et al., 2013. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer research, 73(16), pp.5288–5298. Available at: http://dx.doi.org/10.1158/0008-5472.CAN-13-0874.

Lawrence MG. et al., 2013. A preclinical xenograft model of prostate cancer using human tumors. Nature protocols, 8(5), pp.836–848. Available at: http://dx.doi.org/10.1038/nprot.2013.043.

Chambers KF, Pearson JF, Aziz N, O’Toole P, Garrod D, Lang SH. Stroma Regulates Increased Epithelial Lateral Cell Adhesion in 3D Culture: A Role for Actin/Cadherin Dynamics. Chin W-C, editor. PLoS ONE. 2011 Apr 18;6(4):e18796. Available from: http://dx.plos.org/10.1371/journal.pone.0018796

Chambers KF, Pearson JF, Pellacani D, Aziz N, Gužvić M, Klein CA, Lang SH. Stromal upregulation of lateral epithelial adhesions: Gene expression analysis of signalling pathways in prostate epithelium. Journal of Biomedical Science. 2011;18(1):45. Available from: http://www.jbiomedsci.com/content/18/1/45

Lang SH, Anderson E, Fordham R, Collins AT. Modeling the Prostate Stem Cell Niche: An Evaluation of Stem Cell Survival and Expansion In Vitro. Stem Cells and Development. 2010 Apr;19(4):537–46. Available from: https://www.liebertpub.com/doi/10.1089/scd.2009.0291

Lang S, Frame F, Collins A. Prostate cancer stem cells. The Journal of Pathology. 2009 Jan;217(2):299–306. Available from: http://doi.wiley.com/10.1002/path.2478

Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH, et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biology. 2008;9(5):R83. Available from: http://genomebiology.biomedcentral.com/articles/10.1186/gb-2008-9-5-r83

Lang SH, Smith J, Hyde C, Macintosh C, Stower M, Maitland NJ. DIFFERENTIATION OF PROSTATE EPITHELIAL CELL CULTURES BY MATRIGEL/ STROMAL CELL GLANDULAR RECONSTRUCTION. In Vitro Cellular & Developmental Biology - Animal. 2006;42(8):273. Available from: http://link.springer.com/10.1290/0511080.1

Collins AT, et al., 2005. Prospective identification of tumorigenic prostate cancer stem cells. Cancer research, 65(23), pp.10946–10951. Available at: http://dx.doi.org/10.1158/0008-5472.CAN-05-2018.

Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. Journal of Cell Science. 2004 Jul 15;117(16):3539–45. Available from: http://jcs.biologists.org/cgi/doi/10.1242/jcs.01222

Lang SH, Sharrard RM, Stark M, Villette JM, Maitland NJ. Prostate epithelial cell lines form spheroids with evidence of glandular differentiation in three-dimensional Matrigel cultures. British Journal of Cancer. 2001 Aug;85(4):590–9. Available from: http://www.nature.com/doifinder/10.1054/bjoc.2001.1967

Collins AT. et al., 2001. Identification and isolation of human prostate epithelial stem cells based on α2β1-integrin expression. Journal of cell science, 114(21), pp.3865–3872. Available at: http://jcs.biologists.org/content/114/21/3865.short [Accessed February 8, 2019].

Robinson EJ, Neal DE & Collins AT, 1998. Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. The Prostate, 37(3), pp.149–160. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9792132.